Novo Nordisk A/S

NOVO B

DK0062498333

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Employees

69,260

Sector

Pharmaceuticals

Calendar

2024-11-06 - Q3 2024 Earnings Release

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

NOVO NORDISK : Q2 miss; recent market fears should be capitalised on by long-term investors

August 07, 2024 at 09:48 am EDT

Lars Fruergaard Jorgensen, CEO of Novo Nordisk on guidance, Wegovy and US Market

August 07, 2024 at 06:07 am EDT

Novo Nordisk doesn't disappoint

January 31, 2024 at 10:48 am EST

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

903.40DKK

Average target price

967.54DKK

Spread / Average Target

+7.10%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-09-17 am EDT			5-day change	1st Jan Change
903.40 ^DKK	-2.03%		+1.85%	+29.41%

01:16am	Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports	RE
Sep. 17	Health Care Down as Novo Nordisk Slides on Drug-Price Fears - Health Care Roundup	DJ

Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports	07:16pm	RE
Health Care Down as Novo Nordisk Slides on Drug-Price Fears - Health Care Roundup	Sep. 17	DJ
Sector Update: Health Care Stocks Retreat Late Afternoon	Sep. 17	MT
Sector Update: Health Care	Sep. 17	MT
Novo Nordisk's Ozempic Likely to Face U.S. Price Negotiations, Bloomberg Reports	Sep. 17	DJ
US Senator Sanders says generic drugmakers could sell Ozempic for less than $100/month	Sep. 17	RE
Novo Nordisk Exec Says Ozempic 'Very Likely' to Face Drug Price Negotiations	Sep. 17	MT
Novo Nordisk Exec Says Ozempic 'Very Likely' to Face Drug Price Negotiations, Bloomberg Reports	Sep. 17	MT
Korro Bio Partners With Novo Nordisk to Develop Genetic Medicines	Sep. 16	MT
Korro Bio, Inc Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates	Sep. 16	CI
Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production	Sep. 12	RE
NOVO NORDISK : Deutsche Bank keeps its Buy rating	Sep. 12	ZD
Roche shares drop on side effects result in early-stage obesity pill trial	Sep. 12	RE
Health Care Down on Cyclical Bias -- Health Care Roundup	Sep. 11	DJ
Sector Update: Health Care Stocks Narrowly Mixed Premarket Wednesday	Sep. 11	MT
Novo Nordisk's Experimental Obesity Pill Could Be More Effective With Extended Use	Sep. 11	DJ
NOVO NORDISK : JP Morgan reiterates its Buy rating	Sep. 11	ZD
NOVO NORDISK : Gets a Neutral rating from UBS	Sep. 11	ZD
Novo Nordisk Reports Positive Results of Phase 3a Trial of Anti-Obesity Drug Liraglutide in Children	Sep. 11	MT
Health Care Up on Defensive Bias -- Health Care Roundup	Sep. 10	DJ
Weight-loss market to see 16 new drugs by 2029, report estimates	Sep. 10	RE
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower	Sep. 06	MT
Novo Nordisk to present advances in diabetes treatment	Sep. 06	CF
Are thematic ETFs useless?	Sep. 06
Veeva Systems: leader in cloud solutions for the life sciences industry	Sep. 06

Novo Nordisk A/S

Equities